CDH Investments Management
Chinese fresh produce retailer Benlai raises $200m
Chinese online fresh produce retailer Benlai Group has raised $200 million in the first tranche of a Series D round led by Mingde Holding. Existing investors Gaorong Capital and CDH investments re-upped.
PE-owned Belle to spin-out Chinese sports retail business
Belle International – the Chinese footwear retailer privatized by Hillhouse Capital and CDH Investments just over two years ago – is spinning out its sports retail unit through an IPO.
CDH joins Series D for Chinese AI truck player
CDH Investments has participated in the $120 million second tranche of a Series D round for TuSimple, a China and US-based developer of autonomous driving technology for trucks.
CDH wealth management unit to raise emerging markets fund
CDH Investments’ wealth management platform, which sources investment opportunities for the firm’s network of high net worth clients, is raising a $200 million emerging markets fund that will primarily target India.
PE-backed Mabpharm trades down after $157m HK IPO
Mabpharm, a China-based biopharmaceutical company backed by CDH Investments, saw its stock drop almost 20% on debut following a HK$1.23 billion ($157 million) IPO in Hong Kong.
China's Yunji completes $121m US IPO, gains 29% on debut
Yunji, a Chinese membership-based e-commerce platform, gained 29% on its NASDAQ trading debut following a $121 million IPO that was largely covered by two of its private equity investors.
China AI: Deep questions
Concerns around valuations, commercialization timelines, deal targeting, and brand perceptions are coming into focus as China’s AI ecosystem catapults to global prominence
IDG, CDH back China cancer testing kits producer
IDG Capital Partners and CDH Investments have led an RMB300 million ($45 million) Series B round for China-based Creative Biosciences, a manufacturer of testing kits for colon cancer.
China social e-commerce platform Yunji targets US IPO
Yunji, a Chinese membership-based e-commerce platform that typically works with small-scale retailers that don’t have the resources to compete online, has filed to list in the US.
GPs bullish on Chinese IPOs - AVCJ Forum
Private equity investors believe it will become easier to take companies public in China as the country steps up the pace of capital markets reform, creating a system that is more in line with international norms.
China investment: Looking up in a downturn
Private equity firms that held back from investing in 2018 as uncertainty gripped China’s economy now see reasons to get busy again. With few macro tailwinds, GPs will be judged on their ability to pick winners
CDH targets $1b for second China growth fund
CDH Investments is seeking approximately $1 billion for its second China growth fund, just over two years after raising $800 million for the debut vehicle.
Deal focus: Medbanks brings big data to China cancer care
Medbanks raises a $59 million Series C round to update the traditional information networks that make China’s growing oncology industry tick. Quality of management has proven a critical investment factor
Chinese cancer database provider Medbanks raises $59m
Beijing and Shanghai-based Medbanks, an information service provider specializing in cancer care, has raised RMB400 million ($59 million) in Series C funding led by CLP Fund.
CDH leads Series A for Chinese commercial rocket launch player
Chinese commercial rocket developer iSpace has completed an extended Series A round of undisclosed size led by CDH Investments, with participation from Matrix Partners China and local VC Dianke Xinghe.
Operational value-add: Sweat equity
As Asian GPs trial a range of operational value-add strategies with an eye on shifting market dynamics, they are discovering that helping portfolio companies requires self-inspection
China PE outlook: End of the party
Growth stage technology deals have retained a strong following in 2018, but elsewhere in Chinese private equity the mood is more somber
CDH-backed Certusnet files for HK IPO
Certusnet, a China-based developer of telecommunication software backed by CDH Investments, has filed for an IPO in Hong Kong.
Chinese corporate-PE partnerships: Meeting of minds
Collaborative deals between private equity firms and Chinese strategic players reflects the more diverse range of corporates seeking outbound deals - and also a recognition among GPs that they need help growing newly-acquired assets in China
GPs support $590m investment in take-private target China Biologic
China Biologic Products, a US-listed biopharmaceuticals player that was subject to two take-private offers, said it was set to raise $590 million by issuing new shares to investors including Centurium Capital, CITIC Capital, and Hillhouse Capital.
CDH-backed Mabpharm files for Hong Kong IPO
Mabpharm, a China-based biopharmaceutical company backed by CDH Investments, has filed for an IPO in Hong Kong, the latest in a growing number of proposed listings under new rules that allow biotech companies with no revenue or profits to go public.
China Biologic Products receives competing take-private offer
US-listed China Biologic Products has received a buyout offer worth $3.9 billion from a consortium including former CEO David Gao and CDH Investments. It follows a $3.6 billion bid last month by CITIC Capital.
Chinese investors back Indian online marketplace Cashify
Cashify, an Indian online marketplace for used smart phones and electronics, has raised a $12 million funding round led by China-based GPs CDH Investments and Morningside Capital.
Australia-listed Sirtex accepts CDH's $1.4b buyout offer
Australian medical device manufacturer Sirtex Medical has accepted a A$1.9 billion ($1.4 billion) buyout offer from China’s CDH Investments, pulling the plug on an earlier agreement with US-listed Varian Medical Systems.